Using FDA’s New Drug Development Tool: Start With Narrow Context Of Use
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
As FDA gains experience with its new Drug Development Tool qualification process, the agency has found that a narrowly defined patient population and condition-specific measures are preferable.